Health Care & Life Sciences » Biotechnology | Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
20,063.00
30,925
Cost of Goods Sold (COGS) incl. D&A
258.00
247.00
317.00
-
-
Gross Income
258.00
247.00
317.00
-
-
SG&A Expense
9,061.00
14,547.00
32,349.00
57,554.00
72,667
EBIT
9,319.00
14,794.00
32,666.00
37,897.00
42,269
Unusual Expense
1,769.00
83.00
4,719.00
-
-
Non Operating Income/Expense
-
-
34.00
-
-
Pretax Income
11,072.00
14,858.00
37,177.00
36,957.00
39,723
Consolidated Net Income
11,072.00
14,858.00
37,177.00
36,957.00
38,924
Net Income
11,072.00
14,858.00
37,177.00
36,957.00
38,924
Net Income After Extraordinaries
11,072.00
14,858.00
37,177.00
36,957.00
38,924
Net Income Available to Common
11,218.00
14,933.00
37,735.00
36,957.00
38,924
EPS (Basic)
0.64
0.86
5.80
2.09
1.74
Basic Shares Outstanding
17,448.60
17,448.60
6,501.80
17,694.50
22,364.50
EPS (Diluted)
0.64
0.86
5.80
2.09
1.74
Diluted Shares Outstanding
17,448.60
17,448.60
6,501.80
17,694.50
22,364.50
EBITDA
9,061.00
14,547.00
32,349.00
37,491.00
41,742
Non-Operating Interest Income
16.00
19.00
242.00
940.00
2,546
Preferred Dividends
146.00
75.00
558.00
-
-

About Protagonist Therapeutics

View Profile
Address
7707 Gateway Boulevard
Newark California 94560
United States
Employees -
Website http://www.protagonist-inc.com
Updated 07/08/2019
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It offers proprietary peptide technology platform, which discovers and develops new chemical entities to address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.